Company profile
BRIGHT MINDS BIOSCIENCES INC.
NASDAQ:DRUGBiotechnology: Pharmaceutical Preparations
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07266324 | phase2 | not_yet_recruiting | 2026-01-01 | 2026-11-01 | Bright Minds Biosciences Pty Ltd | A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome. |
| NCT05397041 | phase1 | completed | 2022-06-06 | 2023-05-04 | Bright Minds Biosciences Pty Ltd | A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers |
| NCT06401538 | phase2 | recruiting | 2024-12-05 | 2025-09-15 | Bright Minds Biosciences Pty Ltd | BMB-101 in Absence Epilepsy and DEE |
FDA applications (0)
No records yet.